One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

Antibody makeup influences the severity of flu. Viruses are the fastest-evolving biological entity on earth. This fact ...

Discover a novel approach to reduce relapse rates for blood cancers treated via the revolutionary CAR T-cell therapy.

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...

It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...

A novel test enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient. This simple and innovative test provides ...